S
Syndax Pharmaceuticals
Focused on developing an HDAC inhibitor for solid tumors and hematological tumors
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer patients. The company primarily serves patients with difficult-to-treat cancers, including hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Syndax operates in the highly competitive oncology market, which involves the development and sale of drugs and treatments for various types of cancer.
Read full description
The company's business model revolves around research and development (R&D) of new cancer therapies, conducting clinical trials to test their efficacy and safety, and eventually bringing these therapies to market. Syndax generates revenue through the sale of its pharmaceutical products once they receive regulatory approval. Additionally, the company may engage in partnerships or licensing agreements with other pharmaceutical companies to further monetize its innovations.
Syndax's flagship product, Entinostat, is currently undergoing clinical trials in combination with Exemestane for the treatment of HR+, HER2- breast cancer. The results of these trials are crucial for the company's future growth and market positioning. The company has also been active in raising capital through public offerings of common stock, which helps fund its ongoing R&D efforts and operational expenses.
In summary, Syndax Pharmaceuticals is dedicated to advancing cancer treatment through innovative drug development, targeting underserved patient populations, and leveraging clinical trial results to bring new therapies to market. The company's financial health is supported by strategic capital raises and a focus on high-potential oncology treatments.
At a glance
- Founded
- 2005
- Headquarters
- Waltham, United States
- Listing
- IPO 2016
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Syndax Pharmaceuticals.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
MPM BioImpact
Domain Associates
Avalon Ventures
RMI Partners- FVForward Ventures
Series B and later13 investors entered at this stage
Fidelity Investments
Delos Capital
BioMed Ventures
Foresite Capital
Jennison Associates
Cormorant Asset Management
EcoR1 Capital
Aisling Capital
OrbiMed
ArrowMark Partners
BVF Partners
Hercules Capital
Tavistock Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
19 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Syndax Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Syndax Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.